Search results
Results from the WOW.Com Content Network
Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Specific HCV elimination targets include a 90% reduction in incidence and prevalence, treatment of 80% of eligible persons with chronic infection, a 65% reduction in HCV-related deaths, and universal access to key prevention and treatment services [1].
In the current DAA era of hepatitis C treatment, therapy is safe, effective, of relatively short duration, and curative in most people [1, 17]. Widespread use of recommended initial treatment regimens has the potential to substantially reduce hepatitis C prevalence.
This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and ...
Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens. Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy. Initial Treatment of HCV Infection - Choose Patient Genotype.
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Debika Bhattacharya1, Andrew Aronsohn2, Jennifer Price3, Vincent Lo Re III4 and the AASLD-IDSA HCV Guidance Panel*
Recommendations for Testing, Managing, and Treating Hepatitis C | HCV ...
In general, those with harder to treat conditions (HCV genotype 3 and/or cirrhosis) are recommended to extend therapy by an additional 4 weeks if more than 8 days of therapy are missed and HCV RNA is undetectable when assessed at the time of incomplete adherence.
Recommendations are listed by recommended vs alternative and by genotypic activity, evidence level, and alphabetically. Abbreviations: CTP, Child–Turcotte–Pugh score; HCV, hepatitis C virus; NS5A, hepatitis C virus nonstructural protein 5A; RAS, resistance-associated substitution.
For patients with compensated cirrhosis, addition of weight-based ribavirin is recommended (rating IIa, C). Extension to 24 wk should be considered in extremely difficult cases (eg, genotype 3 infection with compensated cirrhosis) or failure following sofosbuvir + glecaprevir/pibrentasvir therapy.